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Abstract
Olanzapine is the one of first line antipsychotic drug for schizophrenia and other serious mental illness. However, it is
associated with troublesome metabolic side-effects, particularly body weight gain and obesity. The antagonistic affinity to
histamine H1 receptors (H1R) of antipsychotic drugs has been identified as one of the main contributors to weight gain/
obesity side-effects. Our previous study showed that a short term (2 weeks) combination treatment of betahistine (an H1R
agonist and H3R antagonist) and olanzapine (O+B) reduced (245%) body weight gain induced by olanzapine in drug-naı̈ve
rats. A key issue is that clinical patients suffering with schizophrenia, bipolar disease and other mental disorders often face
chronic, even life-time, antipsychotic treatment, in which they have often had previous antipsychotic exposure. Therefore,
we investigated the effects of chronic O+B co-treatment in controlling body weight in female rats with chronic and
repeated exposure of olanzapine. The results showed that co-administration of olanzapine (3 mg/kg, t.i.d.) and betahistine
(9.6 mg/kg, t.i.d.) significantly reduced (251.4%) weight gain induced by olanzapine. Co-treatment of O+B also led to a
decrease in feeding efficiency, liver and fat mass. Consistently, the olanzapine-only treatment increased hypothalamic H1R
protein levels, as well as hypothalamic pAMPKa, AMPKa and NPY protein levels, while reducing the hypothalamic POMC,
and UCP1 and PGC-1a protein levels in brown adipose tissue (BAT). The olanzapine induced changes in hypothalamic H1R,
pAMPKa, BAT UCP1 and PGC-1a could be reversed by co-treatment of O+B. These results supported further clinical trials to
test the effectiveness of co-treatment of O+B for controlling weight gain/obesity side-effects in schizophrenia with chronic
antipsychotic treatment.
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Introduction
Second generation antipsychotic drugs have surpassed first-
generation agents as the first line of treatment for schizophrenia.
Among them, olanzapine is one of the most widely prescribed
antipsychotic drugs to treat schizophrenia and other serious
mental disorders such as bipolar disorder, dementia, major
depression, and Tourette’s syndrome due to its enhanced
tolerability [1–6]. Unfortunately, olanzapine, along with cloza-
pine, have the highest risk for substantial weight gain, obesity and
other serious metabolic disorders including type II diabetes
mellitus, with increased risk for cardiovascular disease and
premature death [6–13].
Olanzapine has high binding affinities with multiple neuro-
transmitter receptors including dopamine D2, serotonin 5-HT2A
and 5-HT2C, histamine H1 receptors, and muscarinic M1 and M3
receptors [8,14]. While D2 and 5-HT2A receptors play a critical
role in the therapeutic effects of olanzapine [15,16], evidence
indicates that the H1, 5-HT2C, and M3 receptors are involved in
antipsychotic-induced metabolic side-effects [8,9,17–24]. Strong
evidence suggests that H1 receptor antagonism is the key factor
contributing to olanzapine/clozapine-induced weight gain and
obesity [9,18,19,24–26]. In fact, a significant association of
interaction between the genetic variants of H1 receptors
(rs346074-rs346070) and BMI/obesity has been identified recently
in non-affective psychotic disorder patients treated with the high-
H1 receptor affinity antipsychotics olanzapine, clozapine and
quetiapine [27].
Several animal studies have found that olanzapine could
modulate histaminergic neurotransmission for the regulation of
food intake and weight gain in rats [28,29]. Further evidence
showed that weight gain and obesity associated with olanzapine
and clozapine are mediated by activation of the hypothalamic
AMP-activated protein kinase (AMPK) pathway via blockade of
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H1 receptors [25,30–32]. In fact, a recent study revealed an
association between polymorphisms in the AMPK gene and
weight gain induced by olanzapine and clozapine [33]. Addition-
ally, it was reported that olanzapine down-regulates the anorex-
igenic neuropeptide proopiomelanocortin (POMC), but up-regu-
lates the orexigenic neuropeptide Y (NPY), in the arcuate nuclei of
the hypothalamus (Arc) [34–36]. Furthermore, reduced activation
of the brown adipose tissue (BAT) is associated with obesity and
diabetes in humans [37]. The BAT is enriched for uncoupling
protein 1 (UCP1) [38], which is involved in olanzapine-induced
weight gain observed in rat models [39–41]. The peroxisome
proliferator-activated receptor gamma coactivator 1-alpha (PGC-
1a) and PGC-1b control mitochondrial biogenesis, which plays a
critical role in the BAT thermogenesis [42], and is related with
olanzapine-induced weight gain [39,41,43]. There is evidence that
activation of BAT UCP1 and PGC-1a are also modulated by the
hypothalamic H1R-AMPK pathways [44,45]. Therefore, it may
be possible to control the antipsychotic-induced weight gain by
modulating hypothalamic H1 receptors and related pathways.
Recently we found that a short-term (2 weeks) co-treatment with
betahistine (an H1R agonist/H3R antagonist) and olanzapine
resulted in a 245% reduction of weight gain in drug-naı̈ve rats
compared to those treated solely with olanzapine [46]. This
finding was confirmed by a recent short-term (6-week) clinical trial
in which first episode schizophrenia patients with a combination
treatment of olanzapine, betahistine and reboxetine (a selective
norepinephrine reuptake inhibitor) had significantly less weight
gain than those treated with olanzapine only [47], while
betahistine+reboxetine combination treatment produced a two-
fold larger weight-attenuating effect than reboxetine treatment
alone [47,48].
These animal and clinical results from short-term trials
supported the effects of betahistine in attenuating olanzapine-
induced weight gain in drug naı̈ve subjects [46]. It is worth noting
that clinical patients suffering with schizophrenia, bipolar disease
and other mental disorders often face chronic, even life-time,
treatment with antipsychotic drugs [5]. Since betahistine has a
very high safety profile with extremely low (1:100,000) adverse
drug reaction [49], it has a huge potential for chronic management
of antipsychotic-induced weight gain and obesity in schizophrenia
and other mental disorders. It is important to note that
antipsychotics cause a significant body weight gain not only in
drug-naı̈ve patients, but also in chronic patients who usually have
already had previous antipsychotic exposure [5,13,26]. However it
was not clear whether chronic co-treatment of betahistine and
olanzapine would have similar weight-attenuating effects, so this
was addressed in this chronic animal study. Furthermore, the
effects of chronic co-treatment of olanzapine and/or betahistine
on the protein levels of H1 receptors, AMPKa, pAMPKa, NPY
and POMC in the hypothalamus, as well as UCP1, PGC-1a and
PGC-1b levels in the BAT were also investigated.
Materials and Methods
Animals housing and measurements
Forty-eight female Sprague–Dawley rats (201–225 g) were
obtained from the Animal Resources Centre (Perth, WA,
Australia). In order to reduce potential stress caused by
transportation, rats were housed in pairs for 1 week prior to the
start of the experiment. They were allowed ad-libitum access to
water and standard laboratory chow diet (3.9 kcal/g; 10% fat,
74% carbohydrate and 16% protein) throughout the whole
experiment. During the experiment, they were housed in
individual cages under environmentally controlled conditions
(22uC, light cycle from 07:00 to 19:00 and dark cycle from
19:00 to 07:00). Body weight, food intake and water intake were
measured twice per week. All experimental procedures have been
approved by the Animal Ethics Committee, University of
Wollongong, Australia (AE11/10); and complied with the
Australian Code of Practice for the Care and Use of Animals for
Scientific Purposes (7th edition, 2004).
Drug preparation and treatment
Prior to drug treatment, rats were trained for oral treatment
procedures by feeding cookie-dough without drugs (0.3 g) for one
week. In brief, the pellets with drugs were made prior by mixing
droplets of water with cookie dough powder (containing 30.9%
cornstarch, 30.9% sucrose, 6.3% gelatine, 15.5% casein, 6.4%
fibre, 8.4% minerals, and 1.6% vitamins) [46,50,51]. Controls
received an equivalent pellet without drug. Rats were observed
during treatment administration to ensure complete consumption
of the medication pellet. Water bottles were carefully monitored
for leakage, and cages were checked for uneaten food.
Rats were administered the treatments in 3 phases (Figure 1A).
In Phase 1, 48 rats were divided into two groups during the first
3.5 weeks (Day 0–23); one half of them (n= 24) were treated with
olanzapine (1 mg/kg, t.i.d.), and the other half treated with
vehicle. In Phase 2, from Day 23, olanzapine was withdrawn for
19 days; all rats did not receive any treatment during this period.
In Phase 3, from week 6, the two groups were divided into 4 sub-
groups (n = 12) for further treatment of 5 weeks (Figure 1A): (1)
olanzapine (1 mg/kg, t.i.d.), (2) co-treatment of olanzapine and
betahistine, (3) betahistine (9.6 mg/kg, t.i.d.), and (4) control
(vehicle). Drugs were administrated at the dosages mentioned
above 3 times per day (07:00h, 14:00h, and 23:00h; with
861 hour interval).
After completing treatment, all rats were sacrificed (without
fasting) by carbon dioxide asphyxiation. Post-mortem white
adipose tissue including perirenal, periovary, inguinal and
mesentery fat, sub-scapular brown adipose tissue, as well as the
liver, were dissected and individually weighed [46,52]. Body length
and femur length were also measured and recorded to ascertain
the effect of body growth on the body weight of rats.
Liver histology
The liver lipid accumulation was examined using haematoxylin
and eosin stains (HE; Sigma, St Louise, USA) [53,54]. In brief,
frozen livers of rats were sectioned 10 mm thick using a cryostat
(LEICA, Wetzlar, Germany) and the slides were air dried at room
temperature for 60 minutes. Then they were fixed with ice cold
10% formalin for 5 minutes, followed by air drying for another
60 minutes and rinsed immediately in 3 changes of distilled water.
For HE staining, after drying the slides for 30 seconds at room
temperature, they were placed in xylene for 1 minute, followed by
100%, 95%, 80% and 70% ethanol for 1 minute, respectively.
After dipping in distilled water for 30 seconds, haematoxylin
staining was performed for 5 minutes, dipping into dH2O again,
and then placing the slides in Eosin solution for 2 minutes. The
dehydration procedures were performed as follows: after the slides
were dipped in dH2O, 70%, 80%, 95% and 100% ethanol were
conducted for 30 seconds or 1 minute.
Western blotting
Brain samples were taken 2 hours after the final drug treatment.
Using the micro-dissection procedures established in our labora-
tory [32,36], the hypothalamic nuclei were dissected. The
dissection targeted the Arc in an overlapping pattern over the
third ventricle [55]. Since the Arc is small, the punched tissue
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contained Arc and adjacent ventromedial nucleus (VMH);
therefore the punched tissue was labelled as the mediobasal
hypothalamus. The dissected brain tissue was placed into 0.5 mL
Precellys Homogenising tubes and homogenised in ice-cold
homogenising buffer [9.8 ml NP40 cell lysis buffer (Invitrogen,
Camarillo, CA, USA), 100 ml b-Glycerophosphate (50 mM;
Invitrogen), 33.3 ml PMSF (0.3M; Sigma-Aldrich, St Louis, MO,
USA), and 100 ml Protease Inhibitor Cocktail (Sigma-Aldrich)].
The total protein concentrations of the tissue lysate were
determined by the Bio-Rad DC Protein Assay (500-0116, Bio-
Rad, Hercules, CA, USA) with bovine serum albumin (BSA) as a
standard. The samples were centrifuged, and the supernatants
were collected and stored at 280uC until required.
Homogenised brain samples containing 10 mg of protein were
first heated at 95uC using a digital dry bath (Labnet International,
USA) for 15 minutes in loading buffer containing 950 ml laemmli
buffer (Bio-Rad) and 50 ml b-mercaptoethanol (Sigma-Aldrich) to
denature the protein of the samples. Then, the samples were
loaded into CRTGEL4–12% Bis-Tris Polyacrylamide Gels (Bio-
Rad) including one channel of Precision plus Dual Colour protein
Standards (Bio-Rad). The samples were subjected to electropho-
resis in 16 XT-MOPS running buffer [50 ml 206 XT-MOPS
running buffer (Bio-Rad) and 950 ml distilled water] at 100 V for
15 minutes followed by 200 V for 55 minutes. The separated
proteins were then transferred electrophoretically onto a non-
specific protein binding polyvinylidene difluoride (PVDF) mem-
brane (Bio-Rad) in the ice cold transfer buffer (150 ml 106Tris/
Glycine Buffer (Bio-Rad), 300 ml cold methanol and 1050 ml
distilled water) at 100 V for one hour. The PVDF membranes
were incubated in the Tris-Buffered Saline-Tween (TBST) (Sigma-
Aldrich) solution containing 5% BSA for one hour at room
temperature for blocking the remaining non-specific protein
binding pores on the PVDF membrane. Each membrane was
then incubated in the primary antibodies including anti-AMPKa
(1:1000; Cell Signaling Technology, Beverly, MA, USA, #2532),
anti-phospho-AMPKa (1:1000; Cell Signaling, #2535) and anti-
histamine H1 (1:1000; Santa Cruz Biotechnology, Dallas, USA,
#SC-20633), anti-POMC (1:1000, Santa Cruz, # SC-20148),
anti-UCP1 (1:1000; Santa Cruz Biotechnology, #SC-6529), anti-
PCG-1a (1:1000; Santa Cruz Biotechnology, #SC-13067) and
anti-PGC-1b (1:1000; Abcam, #AB130741), which were diluted
in TBST and 1% BSA buffer overnight at 4uC. Each membrane
was washed 365 minutes in TBST buffer, followed by incubation
for 1 hour at room temperature (RT) with horseradish peroxidise
(HRP)-conjugated goat anti-rabbit (1:2000; Millipore, Billerica,
MA, USA) or donkey anti-goat (1:2000, Santa Cruz Biotechnol-
ogy) as secondary antibodies. The membranes were then each
washed 365 minutes in TBST buffer at RT. The proteins of
interest were visualised by reacting the membranes with Luminata
Crescendo Western HRP Substrate (Millipore) via incubation, and
exposing them to Amersham Hyperfilm ECL (GE Healthcare Life
Science). Membranes were then re-probed with mouse anti-actin
primary polyclonal antibody (1:10000; Millipore, Temecula, CA)
and HRP-conjugated rabbit anti-mouse secondary antibody
(1:3000; Millipore, Temecula, CA). The immunoreactive signals
were quantified by densitometry and the values were corrected
based on their corresponding actin levels. All results were
normalised by taking the value of the vehicle group as 100%.
Experiments were performed in duplicate.
Enzyme immunoassay (EIA)
The NPY EIA Kit (Phoenix Pharmaceutical, USA) was
performed to determine the hypothalamic NPY level using the
homogenised hypothalamic Arc tissue, which was prepared for the
above western blot experiments.
Statistical analysis
Statistical analysis was performed using SPSS (version 19.0,
IBM SPSS Statistics, USA). The Kolmogorov-Smirnov test was
used to examine the distribution of data from all experiments.
Body weight gain, food intake and water intake data from Phase 1
and 2 were analysed by two-way ANOVAs (DRUG TREAT-
MENT6TIME as repeated measures). The Phase 3 data on body
weight gain, food intake and water intake were analysed by three-
way repeated ANOVAs (OLANZAPINE6BETAHISTINE6
TIME as repeated measures). Two-way ANOVAs was used to
compare the levels of NPY, H1R, AMPKa, pAMPKa, POMC,
UCP1, PGC-1a and PGC-1b. Multiple comparisons were
performed using a post-hoc Dunnett-T test. Pearson’s or Spearman
correlation tests were used to assess the relationships among these
Figure 1. Effects of olanzapine and/or betahistine treatment on body weight gain. A: Outline of the experimental design. B: The trend of
three phases of drug administration on the accumulated body weight side-effect. Olanzapine (1 mg/kg, t.i.d.; n = 12), betahistine (9.6 mg/kg, t.i.d.;
n = 12), co-treatment (O+B; n = 12) or control (vehicle; n = 12) for 11 weeks. (¤: controlN: olanzapine, x: betahistine, m: O+B co-treatment). * p,0.05,
** p,0.01 vs. control, # p,0.05 vs. olanzapine.
doi:10.1371/journal.pone.0104160.g001
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measurements. For the data without abnormal distribution, a
Mann-Whitney U test was applied. All data were presented as
mean 6 SEM, and statistical significance was accepted when p,
0.05.
Results
Effects of olanzapine and/or betahistine on weight gain,
food intake and feeding efficiency
Phase 1. Effects of olanzapine treatment. Figure 1B
presents the accumulated body weight gain over the experimental
period. In Phase 1, olanzapine treatment significantly increased
body weight gain compared to vehicle through the treatment
period of 3 weeks (all p,0.001) (Figure 1B). Consistent with
weight gain changes, olanzapine significantly increased food intake
through the treatment period (all p,0.05; Figure 2A). Further-
more, feeding efficiency (grams of body weight gain/grams of food
intake) was significantly elevated by olanzapine treatment com-
pared with the vehicle (p,0.001) (Figure 2B). However, there was
no significant change of water intake in this phase (p.0.05).
Phase 2. Effect of olanzapine withdrawal. Following
olanzapine withdrawal, the weight difference between the
olanzapine-treated rats and vehicle were gradually narrowed:
initially, olanzapine-treated rats had a significantly higher weight
gain than the vehicle group (p,0.001), the weight loss of rats was
detected following olanzapine withdrawal (Figure 1B). The weight
of rats in the olanzapine group then reduced gradually to a level
similar to the rats in the vehicle group after 12 days of olanzapine
withdrawal (p.0.05), and remained at the same level as the
control for the rest of the period of olanzapine withdrawal (p.
0.05). Consistent with the changes in weight loss, olanzapine
withdrawal led to a sharp decrease in food intake and remained at
a lower level for 1.5 weeks compared to the vehicle group
(Figure 2C), then gradually returned to a level similar to the
vehicle group (Figure 2C). In contrast to olanzapine treatment,
olanzapine withdrawal caused a significant decrease in feeding
efficiency compared to the vehicle group (p,0.001) (Figure 2D).
Similar to the first phase, no water intake difference between the
groups was identified (p.0.05).
Phase 3. Effect of chronic betahistine co-treatment in
reducing olanzapine-induced weight gain. As shown in
Figure 1A, from week 7 to week 11, the rats were divided into
four groups: olanzapine-only, olanzapine+betahistine (O+B) co-
treatment, betahistine-only, and control (vehicle). In the olanza-
pine-only group, resumed olanzapine treatment significantly
increased body weight gain compared to the control through the
5 weeks treatment period (all p,0.01; Figure 1B). On the other
hand, although the O+B co-treatment group had a higher weight
gain than the control and betahistine-only groups (all p,0.01;
Figure 1B), it appeared to have a significantly lower body weight
gain than the olanzapine-only group after 3 weeks’ co-treatment
(p,0.05; Figure 1B) and in total reduced 251.4% following 5
weeks’ co-treatment (p,0.05). However, the betahistine-only
treatment had no significant difference in weight gain compared
to the control group (all p.0.05; Figure 1B). Therefore, co-
treatment of betahistine and olanzapine can partly reduce/prevent
weight gain induced by chronic olanzapine treatment (Figure 1B).
There were no significant differences in the body or femur length
among all treatment groups and the controls (Table 1), which
suggested that none of the treatments affect animal growth.
The olanzapine-only treatment significantly increased food
intake compared to the control for 3 weeks’ of treatment (p,
0.01; Figure 2E), then gradually reduced to a level similar to other
groups. The O+B co-treatment significantly increased food intake
compared with the control for the first 2 weeks’ of co-treatment
(p,0.01; Figure 2E), then it gradually declined similar to the
control. Although no significant difference in food intake was
detected between the O+B co-treatment group and olanzapine-
only group (Figure 2E), the O+B co-treatment had a significantly
lower feeding efficiency than the olanzapine-only treatment group
(p,0.05). Therefore, O+B co-treatment was effective in decreasing
feeding efficiency compared to the olanzapine-only treatment.
Fat deposits
Compared to the control, rats with olanzapine-only treatment
had a significantly higher inguinal fat mass (p,0.01), periovary fat
(p,0.05), and mesentery fat (p = 0.01; Table 1). The olanzapine-
only treatment group also had significantly higher inguinal fat (p,
0.01), perirenal fat (p,0.05), periovary fat (p,0.01), and
mesentery fat (p,0.01) than betahistine-only treatment. It is
important that the rats with O+B co-treatment had significantly
less inguinal fat mass than those with olanzapine-only treatment
(p = 0.015) and tended to have less periovary fat (p = 0.094) and
mesentery fat (p = 0.074) than olanzapine-only treatment group
(Table 1). However, there was no significant difference in sub-
scapula brown fat mass among all treatment groups and controls
(Table 1).
Liver weight and morphological changes
The rats with olanzapine-only treatment had significantly
higher liver weight than controls (p,0.01) and those with
betahistine-only treatment (p,0.01, Table 1). In contrast, the rats
with O+B co-treatment had significantly lower liver weight than
those with olanzapine-only treatment (p,0.05). Consistently, the
HE stain showed that there was a significantly higher fat cell count
in the olanzapine-only treatment group than controls, while there
was a significantly lower fat cell count in the O+B co-treatment
group than the olanzapine-only group (p,0.001; Figure 3E). In
addition, the olanzapine-only group tended to have larger total fat
cell areas than the control (p=0.073) and the O+B co-treatment
group (p=0.086; Figure 3F).
Effects of olanzapine and/or betahistine treatment on
the protein expression of hypothalamic H1R, AMPKa,
pAMPKa, NPY and POMC
Compared to the control, olanzapine treatment significantly
increased the protein levels of H1R (+37%, p=0.003; Figure 4A
and B). The O+B co-treatment significantly decreased H1R
expression compared with the olanzapine-only treatment (226%,
p=0.009; Figure 4A and B). In terms of the protein expression of
AMPKa, both olanzapine-only and co-treatment of O+B signif-
icantly enhanced the AMPKa level compared to the control
(olanzapine only vs. control, +22%, p=0.015; co-treatment of O+
B vs. control, +20%, p=0.025; Figure 4A and C). Both
olanzapine-only treatment and co-treatment of O+B significantly
enhanced the protein expression of pAMPKa compared with the
control (olanzapine only vs. control, +51%, p=0.001; co-
treatment of O+B vs. control, +29%, p=0.047; Figure 4A and
D). However, the O+B co-treatment reduced the pAMPKa
protein level compared with olanzapine-only treatment at a
borderline significance (222%, p=0.054; Figure 4A and D).
Additionally, the NPY peptide was significantly up-regulated by
olanzapine-only treatment (p=0.047), and co-treatment of O+B
tended to elevate the NPY level compared to controls (p=0.055)
(Figure 4F). On the other hand, compared with the control,
olanzapine-only treatment had a significant effect in decreasing
hypothalamic POMC protein levels (252%, p=0.016), while co-
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treatment of O+B had no effect on POMC levels (p.0.05;
Figure 4A and E).
Hypothalamic H1R protein expression was positively correlated
with total body weight gain (r=0.403, p=0.028), total food intake
(r=0.486, p=0.009) and tended to correlate with feeding
efficiency (r=0.207, p=0.085). In addition, the hypothalamic
AMPKa expression also positively correlated with body weight
gain (r=0.750, p=0.000), total food intake (r=0.553, p=0.003)
and feeding efficiency (r=0.617, p=0.001). The protein expres-
sion of hypothalamic pAMPKa was positively correlated with total
body weight gain (r=0.668, p=0.000), total food intake
(r=0.515, p=0.006), as well as feeding efficiency (r=0.555,
p=0.003). There were positive correlations between hypothalamic
H1R and AMPKa (r=0.518, p=0.006) and pAMPKa (r=0.444,
p=0.017), and, there were negative correlations among hypo-
thalamic POMC protein expression and body weight gain (r=
20.456, p=0.014) and feeding efficiency (r=20.435, p=0.019).
The hypothalamic NPY peptide level was positively correlated
with body weight gain (r=0.382, p=0.036), and feeding efficiency
(r=0.392, p=0.032).
Effects of olanzapine and/or betahistine treatment on
the protein expression of UCP1, PGC-1a, and PGC-1b in
brown adipose tissue
Olanzapine significantly down-regulated BAT UCP1 protein
expression by 44% (p=0.024), compared with the control, while
co-treatment of O+B significantly reversed the decreased UCP1
protein level by 43% caused by the olanzapine only treatment
(p=0.037) (Figure 5A and B). Similarly, BAT PGC-1a protein
expression was downregulated by 21% (p=0.037) under olanza-
pine-only treatment, whilst, it was reversed significantly by co-
treatment of O+B (p=0.023, Figure 5A and C). However, for
PGC-1b protein expression, no any significant change was
observed among the treatment groups (all p.0.05). Additionally,
Figure 2. Effects of olanzapine and/or betahistine treatment on food intake and feeding efficiency. A–B: Accumulated food intake (A)
and feeding efficiency (B) in the first phase of olanzapine treatment (1 mg/kg, t.i.d.; n = 12) compared with vehicles. C–D: Food intake (C) and Feeding
efficiency (D) following olanzapine withdrawal. E–F: Food intake (E) and feeding efficiency (F) following chronic treatment of olanzapine (1 mg/kg,
t.i.d.; n = 12), betahistine (9.6 mg/kg, t.i.d.; n = 12), co-treatment (O+B; n = 12) or vehicle (control; n = 12) for 5 weeks. (¤: control N: olanzapine, x:
betahistine, m: O+B co-treatment). * p,0.05, ** p,0.01, olanzapine vs. control; $ p,0.05, $$ p,0.01, co-treatment of O+B vs. control; # p,0.05 O+B
vs. olanzapine.
doi:10.1371/journal.pone.0104160.g002
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BAT UCP1 and PGC1-a expressions in the BAT were negative
correlated with hypothalamic pAMPKa levels (r=20.246,
p=0.051; r=20.374, p=0.040).
Discussion
Long term antipsychotic use remains mainstay treatment in
patients with schizophrenia. Clinical trials in the past two decades
have proven that, whether in first episode/antipsychotic-naı̈ve
patients or in chronic schizophrenia patients with previous
antipsychotic exposure, antipsychotic administration (particularly
olanzapine and clozapine) can cause significant weight gain
[5,7,13,56]. Similar to a previous report [57], the present study
showed a withdrawal of oral olanzapine treatment also resulted in
weight loss that was largely due to the decrease of food intake and
feeding efficiency. Similar to the clinical findings, our results
illustrated that, after drug withdrawal for over 2.5 weeks, the
resumed olanzapine treatment significantly increased body weight
gain [5,15,58,59]. Therefore, this study provided an animal model
which mimicked closely the body weight changes caused by
olanzapine in drug-naı̈ve and re-administered chronic treatment
patients.
The present study was the first in a chronic animal model to
detect the effect of chronic O+B co-treatment on reducing the
body weight gain side-effect in subjects with chronic olanzapine
exposure. The results showed that chronic O+B co-treatment
produces a significant weight-attenuating effect appearing after 1
week and being statistically significant after 3-week co-treatment,
with about ,50% weight gain decrease compared to olanzapine-
only treatment. Previously, a short-term study in drug-naı̈ve rats
found that 2-week O+B co-treatment significantly reduced
(,45%) body weight gain [46]. Consistently with our short-term
experiment, betahistine-only treatment showed no effect on weight
gain and feeding efficiency [46]. A recent clinical trial reported
that antipsychotic drug-naı̈ve schizophrenia patients with a six-
week combination treatment of olanzapine (10 mg, once daily),
betahistine (48 mg, t.i.d.) and reboxetine (4 mg, b.i.d.) (a selective
norepinephrine reuptake inhibitor) had significantly less weight
gain than those on olanzapine only [47]. In addition, a six-week
trial with 3 first episode schizophrenic patients also found that
betahistine (48 mg, t.i.d.) was able to prevent weight gain related
to olanzapine treatment (10 mg, once daily) [60]. It is of note that
both the clinical and animal studies have indicated a time-
dependent effect of antipsychotic (including olanzapine)-induced
weight gain. There are three stages of development of weight
gain/obesity; an early acceleration stage with a rapid increase in
body weight, a middle stage with continuing body weight increase
following at a steadier rate, followed by a ‘‘plateau’’ stage
maintaining a heavier weight with ongoing antipsychotic treat-
ment [58,61]. It is interesting that O+B co-treatment had a
stronger weight gain reducing effects on the ‘‘plateau’’ stage
(Figure 1B). Further studies are worth to investigate the effects if
olanzapine dose was increased at this point, and the effects on the
antipsychotics with less pronounced weight gain side-effects (as a
negative control). The betahistine dosage (9.6 mg/kg rat body
weight) used in this study is equivalent to ,93 mg/kg in humans
(60 kg body weight) according to dosage translation between
species based on body surface area following the FDA guideline
[62]. Betahistine has 3–4 hours of plasma half-life in humans with
one day of urine excretion, but no data showed the half-life of
betahistine in rats [63]. Although there is no data available for the
half-life of betahistine in rats, it is reasonable to suppose that
betahistine is most likely to have a shorter half-life in rats than in
humans. Therefore, the betahistine dosage (9.6 mg/kg rat body
weight) used in this study should be relevant to the human dosage
(48 mg, t.i.d.) used in clinical trials [47,60]. Taken together, results
from the animal model and schizophrenia patients support the
theory that both short-term and chronic co-treatment with
betahistine should be effective to control olanzapine-induced
weight gain in both drug-naı̈ve subjects and those with previous
antipsychotic exposure.
Consistent with the body weight changes in this study, the
olanzapine-only group had more white fat mass and higher liver
weight than the control and betahistine-only groups, which also
corresponded with previous reports [31,46,51,64,65]. On the
other hand, compared to the olanzapine-only treatment, chronic
O+B co-treatment decreased inguinal fat mass and liver weight in
this study. Further HE staining confirmed that olanzapine-only
treatment significantly increased fat accumulation in the liver;
however O+B co-treatment reduced liver fat accumulation. These
results suggested that weight gain decrease in rats treated with O+
B was at least partially from reduced fat accumulation. Further
study is needed to investigate changes in lipid metabolism. There
was no difference in body and femur length among these groups,
which indicated that none of the treatments affected animal
growth.
Table 1. Mean fat mass, liver weight, and body length (mean 6 SEM) in female Sprague Dawley rats treated with olanzapine
(1 mg/kg, t.i.d.) and/or betahistine (9.6 mg/kg, t.i.d.) or control (vehicle).
Control Olanzapine Betahistine O+B
Fat pad mass (g) Inguinal 3.6960.26 5.1760.33** 2.8560.20*,## 4.2560.23#
Perirenal 4.9560.45 5.5460.40 3.7560.37# 5.5860.44
Periovary 6.8160.54 8.8260.65* 5.1760.51## 8.3060.64
Mesentery 2.5460.18 3.4160.30* 2.2360.16## 3.0360.20
Brown Fat 0.3960.03 0.4460.04 0.3760.03 0.3960.02
Liver (g) 12.0960.26 13.7660.44** 12.3560.28## 12.7860.39#
Body Length (cm) 22.3060.21 22.5460.13 22.7160.15 22.4160.10
Femur Length (cm) 5.2660.04 5.1960.02 5.2460.03 5.2060.02
*, p,0.05;
**, p,0.01 vs. control;
#, p,0.05;
##, p,0.01 vs. olanzapine.
doi:10.1371/journal.pone.0104160.t001
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The hypothalamic nuclei, particularly the arcuate nucleus (Arc)
and ventromedial hypothalamus (VMH) play crucial roles in the
regulation of energy homeostasis [20,66,67]. Histamine H1R
antagonists are well documented to increase appetite and obesity
development [18,68]. Several meta-analyses examined the potency
of the antagonistic properties of antipsychotics for H1R, and the
potential to utilise them to predict the likelihood of the obesity
side-effect [19,69,70]. H1R antagonist properties have been
identified as the main predictor for the development of antipsy-
chotic-induced body weight gain/obesity side-effects (approxi-
mately Clozapine.Olanzapine.Risperidone.Haloperidol.Zi-
prasidone.Aripiprazole) [19,20,71,72]. Consistent with these
reports, the present study revealed that olanzapine-only treatment
up-regulated the hypothalamic H1R levels in line with increased
body weight gain and feeding efficiency/hyperphagia induced by
this treatment. To our knowledge, this is the first long term animal
study to investigate the effects of chronic olanzapine and
betahistine co-treatment on hypothalamic H1R expression in the
rat brain. Consistently, a recent study from our group reported
that acute intracerebroventricular (ICV) injection of 2-(3-trifluor-
omethylphenyl histamine (FMPH; an H1R agonist) attenuated
olanzapine induced hyperphagia [32]. It has been noted that
betahistine (as a H3R antagonist) may increase histamine release
Figure 3. Effects of olanzapine and/or betahistine treatment (n=12) on lipid droplet deposition of hepatic tissue. A–C: HE staining of
hepatic tissue from rats treated with Vehicle (A), Olanzapine-only (B), Betahistine-only (C), and O+B co-treatment (D). E: Fat cell counts on the liver
sections of different treatment groups. F: Total fat cell area measured on the liver sections of different treatment groups. ** p,0.01 vs. control; ##
p,0.01 vs. olanzapine.
doi:10.1371/journal.pone.0104160.g003
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via blocking presynaptic H3 autoreceptors, which could augment
its direct agonistic effects on H1R receptors [46].
There is strong evidence that hypothalamic H1R and its linked
AMPK signalling pathways play a crucial role in the antipsychotic-
induced weight gain side-effect [18,24,25]. In fact, several studies
have reported that olanzapine-elevated hypothalamic pAMPK
was linked to its weight gain/metabolic side-effect [25,30,32,73].
In this study, we found that olanzapine only increased pAMPKa
and AMPKa levels in the mediobasal hypothalamus (including the
Arc and VMH) compared with the control. However, the O+B co-
treatment reduced pAMPKa expression compared with olanza-
pine-only treatment. Importantly, there were positive correlations
between pAMPKa and body weight gain, food intake, feeding
efficiency, as well as between AMPKa and body weight gain. Our
findings were confirmed by a recent report by [31] that AMPK
inhibition in the Arc reduced the olanzapine-induced weight gain
side-effects in female rats by means of functional inhibition of
AMPK using adenoviruses carrying dominant negative forms
AMPK (DN-AMPK). This result is also in line with another study
from our group that the acute ICV injection of FMPH (an H1R
agonist) significantly attenuated olanzapine-induced AMPK levels
and food intake [32]. Further investigations is needed to examine
whether O+B co-treatment has different effects on AMPKa
isoforms, and its downstream targets such as acetyl-CoA carbox-
ylase (ACC) and pACC compared with olanzapine-only treat-
ment.
The present study showed that olanzapine downregulated the
protein levels of UCP1 and PGC-1a (biomarkers for thermogen-
esis), but not PGC-1b in the BAT; however these decrease were
reversed by co-treatment with betahistine. The results are
consistent with previous reports that the expression of BAT
UCP1 and PGC-1a protein are decreased by chronic olanzapine
Figure 4. Effects of olanzapine and/or betahistine treatment on the hypothalamic protein levels of histamine H1R, AMPKa,
pAMPKa, and POMC. A: Examples of the images of the western blot experiment showing the protein expressions of histamine H1R, AMPKa,
pAMPKa, POMC and b-actin (n = 6). B–F: Effects of olanzapine and/or betahistine treatment on protein expressions of (B) hypothalamic H1R, (C)
AMPKa, (D) pAMPKa, (E) POMC, (F) neuropeptide Y (NPY). Abbreviations: H1R: H1 receptor, AMPKa: AMPK-activated protein kinase a, pAMPKa: the
AMPK phosphorylation a and POMC: proopiomelanocortin. * p,0.05, ** p,0.01 vs. control; # p,0.05, # p,0.05 vs. olanzapine.
doi:10.1371/journal.pone.0104160.g004
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treatment, which is associated with decreased energy expenditure
and increased feeding efficacy/weight gain induced by chronic
olanzapine treatment [39,40]. Further studies have shown that the
rapid weight gain in the early stage of antipsychotic treatment is
due to a significant increase in food intake (leading to an increase
in feeding efficiency), while weight gain/maintaining heavier
weight following chronic treatment is largely due to decrease in
energy expenditure (such as less activity and reduced thermogen-
esis; also leading to an increase in feeding efficiency) [39,40,58]. In
this study, this time course was confirmed in the rats with repeated
and chronic olanzapine treatment. In the chronic model, we found
that chronic O+B co-treatment reduced feeding efficiency and
increased BAT UCP1 and PGC-1a expressions (suggesting an
increase of thermogenesis in BAT), but did not change food intake.
Consistently, we found that chronic co-treatment with betahistine
did not change the expression of hypothalamic NPY and POMC
induced by olanzapine treatment. In consideration of our previous
findings that the O+B co-treatment did not affect locomotor
activity [46], the BAT UCP1 and PGC-1a changes in this study
suggest that betahistine co-treatment may regulate energy
expenditure by upregulating thermogenesis. Furthermore, this
experiment also revealed that the BAT UCP1 and PGC-1a levels
were negatively correlated with pAMPKa protein levels in the
mediobasal hypothalamus (including the Arc and VMH). Previous
studies reported that AMPK modulated BAT thermogenesis and
UCP1 and PGC-1a expressions [36,45,74,75]. As a result, it is
suggested that betahistine co-treatment may regulate BAT UCP1
and PGC-1a through the hypothalamic H1R-pAMPK pathway.
Therefore, these results suggest that activation of hypothalamic
AMPK contributes to olanzapine-induced weight gain; however
O+B co-treatment may reduce olanzapine-induced weight gain at
least partly through attenuating the H1R-pAMPK activation,
which modulates BAT UCP1 and PGC-1a expression and
upregulates thermogenesis. Since the fasting or food intake
conditions may influence the hypothalamic neuropeptides and
appetite signalling pathways, the hypothalamic changes observed
should considered in the context of rats sacrificed without fasting
in this study.
One of limitation of this study was that plasma olanzapine levels
were not monitored through the experimental periods. According
to dosage translations between the species based on the body
surface area following the FDA guidelines for clinical trials
[51,62,76], the olanzapine dosage used in this project is equivalent
to the recommended dosage for treating schizophrenia patients.
Olanzapine has a shorter half-life in rats compared with humans.
In humans, the half-life of olanzapine in plasma is 24.2 hours,
compared with 72 hours in the brain [15]. However, in the rat, the
half-lives of olanzapine are 2.5 hours and 5.1 hours in the plasma
and brain, respectively, and the high level is retained for 8 hours
after a single dose treatment trough gavage [77]. Therefore, in the
present study, rats were administered with olanzapine three times/
day with 8 hours intervals to ensure a consistently high
concentration for better mirroring the human scenario of oral
administration once per day. This treatment protocol has been
proven to mimic the development of olanzapine-induced body
weight in female rats [36,46,51,58]. In view of the possibility that
betahistine may affect olanzapine metabolism, further studies are
Figure 5. Effects of olanzapine and/or betahistine treatment on the protein levels of UCP1, PGC-1a, and PGC-1b in brown adipose
tissue. A: Examples of the images of the western blot experiment showing the protein expressions of UCP1, PGC-1a, PGC-1b and b-actin (n = 6). B–D:
Effects of olanzapine and/or betahistine treatment on protein expression of (B) UCP1, (C) PGC-1a, and (D) PGC-1b. Abbreviations: UCP1: uncoupling
protein 1, PGC-1a: Peroxisome proliferator-activated receptor gamma coactivator 1-alpha, PGC-1b: Peroxisome proliferator-activated receptor gamma
coactivator 1-beta. * p,0.05, ** p,0.01 vs. control; # p,0.05, # p,0.05 vs. olanzapine.
doi:10.1371/journal.pone.0104160.g005
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also important to detect whether betahistine could affect plasma
olanzapine levels during the O+B co-treatment period.
In this study, compared to olanzapine-only treatment group, the
O+B co-treatment group showed less inguinal fat, and tended to
have less periovary and mesentery fat mass, which suggests an
effect of O+B co-treatment on reducing white fat mass. One
technical limitation in the present study was that the white fat mass
was dissected and weighed from post-mortem rat bodies. The
advanced NMR (nuclear magnetic resonance) analysis may
provide more detailed information about fat mass changes.
Additionally, as olanzapine treatment may cause severe dyslipide-
mia side-effect in patients, therefore it is valuable to investigate
whether O+B co-treatment could reverse olanzapine caused
dyslipidemia in the future studies.
Conclusions
To sum up, this study provides evidence in a rat model that
significant body weight gain induced by olanzapine treatment
could be reversed following drug withdrawal, however unfortu-
nately weight gain resumed after re-introducing olanzapine
treatment. Since patients suffering from schizophrenia and other
mental disorders often require long lasting and repeated antipsy-
chotic treatment, it is very important to control weight gain/
obesity side-effects caused by chronic antipsychotic treatment. In
this study, we found that co-treatment with betahistine is effective
in significantly reducing weight gain induced by olanzapine
through the chronic treatment course. This study further
demonstrated that the mechanisms of betahistine in reducing
olanzapine-induced body weight gain are through the modulation
of the hypothalamic H1R-AMPK-BAT UCP1-PGC-1a pathway.
Extending previous successful trials in drug-naı̈ve subjects in both
animal and first episode schizophrenia patients [46,47,60], this
study provides further evidence to support a clinical trial to test the
effectiveness of co-treatment of olanzapine and betahistine for
controlling the weight gain/obesity side-effect in schizophrenia
with chronic and repeated antipsychotic treatment.
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